Stock GLTO GALECTO, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Galecto, Inc.

Equities

GLTO

US36322Q1076

Delayed Nasdaq
Other stock markets
 16:29:14 09/05/2024 BST 		5-day change 1st Jan Change
0.6902 USD -2.10% Intraday chart for Galecto, Inc. -3.74% -4.14%
05-01 Galecto, Inc. Announces First Patient Dosed in an Investigator-Initiated Phase 2 Trial of GB1211 in Combination with Pembrolizumab CI
04-29 Galecto, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Galecto Announces First Patient Dosed in an Investigator-Initiated Phase 2 Trial of GB1211 in Combination with Pembrolizumab
AQ
Galecto, Inc. Announces First Patient Dosed in an Investigator-Initiated Phase 2 Trial of GB1211 in Combination with Pembrolizumab
CI
Galecto, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Galecto, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Galecto Shares Climb After Bone Marrow Disease Treatment Trial Yields Positive Results
MT
Topline Results from MYLOX-1 Trial Demonstrate Reduction in Fibrosis of the Bone Marrow in Patients with Myelofibrosis
AQ
Galecto, Inc. Announces Positive Topline Results from A Phase 2A Trial of GB2064 for the Treatment of Myelofibrosis
CI
Galecto, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
GALLANT-1: GB1211 Galectin-3 (Gal-3) inhibitor plus atezolizumab (atz) for first line treatment in patients (pts) with advanced/metastatic non-small cell lung cancer (NSCLC)
PU
Galecto Presents Updated Clinical Data at ESMO Congress 2023 and Provides Update on Phase 1b/2a GALLANT-1 Trial
AQ
Galecto, Inc. Presents Updated Clinical Data At ESMO Congress 2023 and Provides Update on Phase 1B/2A Gallant-1 Trial
CI
HC Wainwright Downgrades Galecto to Neutral From Buy
MT
Galecto Announces Plans to Explore Strategic Alternatives
CI
Galecto to Explore Strategic Options, to Reduce Workforce
MT
Galecto, Inc. Announces Executive Changes, Effective October 1, 2023
CI
Galecto, Inc. Proposes to Reduce Its Workforce by 29 People, or Approximately 70% of the Existing Headcount
CI
Galecto Announces Plans to Explore Strategic Alternatives
AQ
Galecto to Present at Investor Conferences in September
AQ
HC Wainwright Adjusts Price Target on Galecto to $2 From $12, Maintains Buy Rating
MT
Sector Update: Health Care Stocks Declining in Late Afternoon Trading
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. GLTO Stock
  4. News Galecto, Inc.